Biosynthetic Heparin
Anticoagulation/Antithrombosis
Pre-clinicalActive
Key Facts
About Optimvia
Optimvia is a private, pre-revenue biotech founded in 2021, headquartered in San Francisco, CA. The company has developed the ADEPT Platform, a computational protein engineering platform, to design novel enzymes and cofactors for synthesizing therapeutics. Its lead program is a biosynthetic heparin, targeting the multi-billion dollar anticoagulant market to replace the current animal-derived supply. The company has established a key partnership with Ginkgo Bioworks to scale manufacturing and is led by a board with expertise in pharmaceuticals, Nobel Prize-winning science, and AI.
View full company profile